NeuDirection Limited has achieved a significant scientific breakthrough with its lead asset, Neu-001, in the field of Alzheimer’s disease (AD) treatment. On January 22, 2026, an independent study published online in the prestigious international journal Cell revealed the novel potential…
NeuDirection Limited (“NeuDirection”) announced that the first healthy subject has been successfully dosed in the Phase I clinical trial for its lead pipeline candidate, Neu-001, a first-in-class small molecule drug for the treatment of amblyopia. The first dose was administered…
NeuDirection Limited is pleased to announce Neu-001 for Injection has received Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) on May 27, 2025. This innovative small molecule therapy is being developed for the treatment of amblyopia.…
The symposium “Advancing Amblyopia Care: Innovations in Clinical Trials and Multisensory Approaches in Neuroscience and Auditory Science” concluded successfully in Hong Kong on April 16,2025, with Neu-Direction playing a pivotal role in advancing the dialogue around cutting-edge therapies for amblyopia. Hosted…
Our first pipeline Neu-001,Neu-001, an innovative first-in-class small-molecule drug for treating amblyopia (commonly known as lazy eye), has received Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA). This milestone achievement was unveiled at a press…